Hiroshi Sasaki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1406033/publications.pdf

Version: 2024-02-01

933447 642732 40 578 10 23 citations h-index g-index papers 47 47 47 560 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Deferred radical prostatectomy in patients who initially elected for active surveillance: a multi-institutional, prospective, observational cohort of the PRIAS-JAPAN study. International Journal of Clinical Oncology, 2022, 27, 194-201.	2.2	4
2	How long is long enough to secure disease control after low-dose-rate brachytherapy in combination with other modalities in intermediate-risk, localized prostate cancer?. International Journal of Clinical Oncology, 2022, 27, 184-193.	2.2	7
3	In Vivo Development of Fetal Pig Kidneys in Mature Monkeys under Clinically Approved Immunosuppressant Drugs. Engineering, 2022, 10, 65-73.	6.7	5
4	Comparison of the medical costs between active surveillance and other treatment for early prostate cancer in Japan: From the data of PRIAS JAPAN study Journal of Clinical Oncology, 2022, 40, 280-280.	1.6	0
5	Pathological and oncological outcomes of off-criteria radical prostatectomy in patients opting for active surveillance: From PRIAS-JAPAN Journal of Clinical Oncology, 2022, 40, 250-250.	1.6	O
6	Clinical significance of unfavorable findings in intermediateâ€risk prostate cancer patients for predicting treatment outcomes after contemporary, doseâ€escalated multimodal radiotherapy. Prostate, 2022, 82, 433-441.	2.3	4
7	Health-related quality of life in Japanese low-risk prostate cancer patients choosing active surveillance: 3-year follow-up from PRIAS-JAPAN. World Journal of Urology, 2021, 39, 2491-2497.	2.2	9
8	Techniques of orthotopic renal transplantation. II. Size-matched porcine grafts in monkey recipients. Acta Cirurgica Brasileira, 2021, 36, e360503.	0.7	4
9	Prognostic Significance of Prostate-Specific Antigen Persistence after Radical Prostatectomy: A Systematic Review and Meta-Analysis. Cancers, 2021, 13, 948.	3.7	13
10	Prognostic value of PSA bounce in prostate cancer following definitive radiation therapy: a systematic review and meta-analysis. Prostate Cancer and Prostatic Diseases, 2021, 24, 976-985.	3.9	6
11	Impact of health-related quality of life on repeat protocol biopsy compliance on active surveillance for favorable prostate cancer: results from a prospective cohort in the PRIAS-JAPAN study. Urologic Oncology: Seminars and Original Investigations, 2021, 40, 56.e9-56.e9.	1.6	2
12	The Impact of ABO Blood Type on Developing Venous Thromboembolism in Cancer Patients: Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2021, 10, 3692.	2.4	4
13	Differences in sex hormone recovery profile after cessation of 12â€week gonadotropinâ€releasing hormone antagonist versus agonist therapy. Andrology, 2021, , .	3.5	2
14	Values of alkaline phosphatase at the diagnosis of castration resistance and response to primary androgen deprivation therapy as predictors of subsequent metastasis in non-metastatic castration-resistant prostate cancer. International Journal of Clinical Oncology, 2020, 25, 479-485.	2.2	1
15	Novel technique to secure closure of the umbilical defect and umbilical reconstruction after laparoscopic resection of urachal remnant. International Journal of Urology, 2020, 27, 1158-1160.	1.0	O
16	The impact of complications after initial prostate biopsy on repeat protocol biopsy acceptance rate. Results from the Prostate Cancer Research International: Active Surveillance JAPAN study. International Journal of Clinical Oncology, 2020, 25, 2107-2114.	2.2	10
17	No survival benefit found after extended treatment with docetaxel for patients with castrationâ€resistant prostate cancer. Prostate, 2019, 79, 1604-1610.	2.3	1
18	Shortâ€term impact of androgen deprivation therapy on bone strength in castrationâ€sensitive prostate cancer. International Journal of Urology, 2019, 26, 980-984.	1.0	9

#	Article	IF	Citations
19	Outcomes of the patients with pTO on first protocol biopsy during active surveillance for early prostate cancer: From the PRIAS-JAPAN study Journal of Clinical Oncology, 2019, 37, 20-20.	1.6	0
20	Earlier use of androgen receptorâ€axisâ€targeted drugs may improve overall survival in patients with nonâ€metastatic castrationâ€resistant prostate cancer. Prostate, 2018, 78, 766-772.	2.3	9
21	Outcomes of laparoscopic resection of urachal remnants followed by novel umbilicoplasty. International Urology and Nephrology, 2018, 50, 2167-2172.	1.4	4
22	Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS): first analysis on survival. International Journal of Clinical Oncology, 2018, 23, 1148-1159.	2.2	21
23	Prospective comparison of the efficacy of caudal versus periprostatic nerve block, both with intrarectal local anesthesia, during transrectal ultrasonography-guided prostatic needle biopsy. Scandinavian Journal of Urology, 2017, 51, 245-250.	1.0	6
24	Lactate dehydrogenase predicts combined progressionâ€free survival after sequential therapy with abiraterone and enzalutamide for patients with castrationâ€resistant prostate cancer. Prostate, 2017, 77, 1144-1150.	2.3	29
25	Do androgen deprivation and the biologically equivalent dose matter in lowâ€doseâ€rate brachytherapy for intermediateâ€risk prostate cancer?. Cancer Medicine, 2016, 5, 2314-2322.	2.8	5
26	Safety of fondaparinux for prevention of postoperative venous thromboembolism in urological malignancy: A prospective randomized clinical trial. International Journal of Urology, 2016, 23, 923-928.	1.0	17
27	A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer. BMC Cancer, 2016, 16, 708.	2.6	6
28	Gonadotropin-releasing hormone antagonist: A real advantage?. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 322-328.	1.6	7
29	Results of central pathology review of prostatic biopsies in a contemporary series from a phase <scp>III</scp> , multicenter, randomized controlled trial (<scp>SHIPO804</scp>). Pathology International, 2015, 65, 177-182.	1.3	2
30	Salvage partial brachytherapy for prostate cancer recurrence after primary brachytherapy. International Journal of Urology, 2014, 21, 572-577.	1.0	24
31	Midâ€term outcome of permanent prostate iodineâ€125 brachytherapy in <scp>J</scp> apanese patients. International Journal of Urology, 2014, 21, 473-478.	1.0	8
32	Pulmonary Metastases After Low-Dose-Rate Brachytherapy for Localized Prostate Cancer. Korean Journal of Urology, 2014, 55, 309.	1,2	3
33	Systemic chemotherapy compared with radiation therapy as adjuvant therapy after radical surgery in high-risk stage IB-IIB cervical adenocarcinoma Journal of Clinical Oncology, 2014, 32, 5598-5598.	1.6	0
34	High-dose-rate (HDR) brachytherapy with external beam radiotherapy for localized high-risk prostate cancer: Five-year results in 122 patients Journal of Clinical Oncology, 2012, 30, 91-91.	1.6	0
35	Transperineal prostate brachytherapy, using I-125 seed with or without adjuvant androgen deprivation, in patients with intermediate-risk prostate cancer: study protocol for a phase III, multicenter, randomized, controlled trial. BMC Cancer, 2010, 10, 572.	2.6	34
36	Upfront transection and subsequent ligation of the dorsal vein complex during laparoscopic radical prostatectomy. International Journal of Urology, 2010, 17, 960-961.	1.0	15

#	Article	IF	CITATION
37	Lateral view dissection of the prostatoâ€urethral junction to reduce positive apical margin in laparoscopic radical prostatectomy. International Journal of Urology, 2009, 16, 664-669.	1.0	17
38	Prostaglandin J2 and Related Compounds Annals of the New York Academy of Sciences, 1994, 744, 161-165.	3.8	34
39	Tumour angiogenesis in prostatic carcinoma with and without bone marrow metastasis: A morphometric study. Journal of Pathology, 1992, 168, 257-262.	4.5	248
40	Impact of adherence to criteria on oncological outcomes of radical prostatectomy in patients opting for active surveillance: data from the PRIAS-JAPAN study. Japanese Journal of Clinical Oncology, 0, , .	1.3	3